Company intelligence / Profile preview

Acticor Biotech

Ownership: Private
Employees: ~31
Development stage: Phase 2

Overview

Acticor Biotech was developing glenzocimab, a humanized monoclonal antibody fragment targeting platelet glycoprotein VI for thrombotic diseases. The company faced significant setbacks in 2024 when its phase 2/3 GREEN study was discontinued due to futility. In January 2025, the Paris Commercial Court declared the company in liquidation proceedings[4].

Therapeutic areas: PulmonologyCardiovascular
Modalities: Monoclonal antibody fragment (Fab)
Industry: Biotech

Drug pipeline

1 asset

glenzocimab

Partnerships

University of BirminghamParis Public Hospitals (Assistance Publique – Hôpitaux de Paris)Queen Elizabeth Hospital BirminghamRothschild Foundation Hospital

Beyond the preview

Go deeper on Acticor Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acticor Biotech.

Explore the full profile